Dual growth factor delivery using biocompatible core-shell microcapsules for angiogenesis

Dong Hoon Choi, Ramesh Subbiah, Ik Hwan Kim, Dong Keun Han, Kwideok Park

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

An optimized electrodropping system produces homogeneous core-shell microcapsules (C-S MCs) by using poly(L-lactic-co-glycolic acid) (PLGA) and alginate. Fluorescence imaging clearly shows the C-S domain in the MC. For release control, the use of high-molecular-weight PLGA (HMW 270 000) restrains the initial burst release of protein compared to that of low-MW PLGA (LMW 40 000). Layer-by-layer (LBL) assembly of chitosan and alginate on MCs is also useful in controlling the release profile of biomolecules. LBL (7-layer) treatment is effective in suppressing the initial burst release of protein compared to no LBL (0-layer). The difference of cumulative albumin release between HMW (7-layer LBL) and LMW (0-layer LBL) PLGA is determined to be more than 40% on day 5. When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA. As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area. This study demonstrates that the fabrication of biocompatible C-S MCs is possible, and that the release control of biomolecules is adjustable. Furthermore, MC-mediated GFs remain in an active form and can upregulate the angiogenic activity of ECs. Core-shell microcapsules are fabricated from immiscible, biocompatible poly(L-lactic-co-glycolic acid) (PLGA) and alginate by using an electrodropping system. They hold the angiogenic growth factors (GFs) vascular endothelial GF (VEGF) in the shell alginate and platelet-derived GF (PDGF) in the core PLGA. The release profile of biomolecules is tunable by employing layer-by-layer assembly or by changing the polymer molecular weight.

Original languageEnglish
Pages (from-to)3468-3476
Number of pages9
JournalSmall
Volume9
Issue number20
DOIs
Publication statusPublished - 2013 Oct 25

Fingerprint

glycolic acid
Capsules
Intercellular Signaling Peptides and Proteins
Acids
Alginate
Biomolecules
Vascular Endothelial Growth Factors
Angiogenesis Inducing Agents
Platelet-Derived Growth Factor
Platelets
Molecular Weight
Fluorescence
Molecular weight
Milk
polylactic acid-polyglycolic acid copolymer
Optical Imaging
Endothelial cells
Human Umbilical Vein Endothelial Cells
Chitosan
Proteins

Keywords

  • angiogenesis
  • core/shell materials
  • electrodropping
  • growth factors
  • microcapsules

ASJC Scopus subject areas

  • Biomaterials
  • Engineering (miscellaneous)
  • Biotechnology
  • Medicine(all)

Cite this

Dual growth factor delivery using biocompatible core-shell microcapsules for angiogenesis. / Choi, Dong Hoon; Subbiah, Ramesh; Kim, Ik Hwan; Han, Dong Keun; Park, Kwideok.

In: Small, Vol. 9, No. 20, 25.10.2013, p. 3468-3476.

Research output: Contribution to journalArticle

Choi, Dong Hoon ; Subbiah, Ramesh ; Kim, Ik Hwan ; Han, Dong Keun ; Park, Kwideok. / Dual growth factor delivery using biocompatible core-shell microcapsules for angiogenesis. In: Small. 2013 ; Vol. 9, No. 20. pp. 3468-3476.
@article{157fa0e6d0a64597a94d3b17a9151e07,
title = "Dual growth factor delivery using biocompatible core-shell microcapsules for angiogenesis",
abstract = "An optimized electrodropping system produces homogeneous core-shell microcapsules (C-S MCs) by using poly(L-lactic-co-glycolic acid) (PLGA) and alginate. Fluorescence imaging clearly shows the C-S domain in the MC. For release control, the use of high-molecular-weight PLGA (HMW 270 000) restrains the initial burst release of protein compared to that of low-MW PLGA (LMW 40 000). Layer-by-layer (LBL) assembly of chitosan and alginate on MCs is also useful in controlling the release profile of biomolecules. LBL (7-layer) treatment is effective in suppressing the initial burst release of protein compared to no LBL (0-layer). The difference of cumulative albumin release between HMW (7-layer LBL) and LMW (0-layer LBL) PLGA is determined to be more than 40{\%} on day 5. When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30{\%} on day 7 with LMW core PLGA and more than 45{\%} with HMW core PLGA. As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area. This study demonstrates that the fabrication of biocompatible C-S MCs is possible, and that the release control of biomolecules is adjustable. Furthermore, MC-mediated GFs remain in an active form and can upregulate the angiogenic activity of ECs. Core-shell microcapsules are fabricated from immiscible, biocompatible poly(L-lactic-co-glycolic acid) (PLGA) and alginate by using an electrodropping system. They hold the angiogenic growth factors (GFs) vascular endothelial GF (VEGF) in the shell alginate and platelet-derived GF (PDGF) in the core PLGA. The release profile of biomolecules is tunable by employing layer-by-layer assembly or by changing the polymer molecular weight.",
keywords = "angiogenesis, core/shell materials, electrodropping, growth factors, microcapsules",
author = "Choi, {Dong Hoon} and Ramesh Subbiah and Kim, {Ik Hwan} and Han, {Dong Keun} and Kwideok Park",
year = "2013",
month = "10",
day = "25",
doi = "10.1002/smll.201300427",
language = "English",
volume = "9",
pages = "3468--3476",
journal = "Small",
issn = "1613-6810",
publisher = "Wiley-VCH Verlag",
number = "20",

}

TY - JOUR

T1 - Dual growth factor delivery using biocompatible core-shell microcapsules for angiogenesis

AU - Choi, Dong Hoon

AU - Subbiah, Ramesh

AU - Kim, Ik Hwan

AU - Han, Dong Keun

AU - Park, Kwideok

PY - 2013/10/25

Y1 - 2013/10/25

N2 - An optimized electrodropping system produces homogeneous core-shell microcapsules (C-S MCs) by using poly(L-lactic-co-glycolic acid) (PLGA) and alginate. Fluorescence imaging clearly shows the C-S domain in the MC. For release control, the use of high-molecular-weight PLGA (HMW 270 000) restrains the initial burst release of protein compared to that of low-MW PLGA (LMW 40 000). Layer-by-layer (LBL) assembly of chitosan and alginate on MCs is also useful in controlling the release profile of biomolecules. LBL (7-layer) treatment is effective in suppressing the initial burst release of protein compared to no LBL (0-layer). The difference of cumulative albumin release between HMW (7-layer LBL) and LMW (0-layer LBL) PLGA is determined to be more than 40% on day 5. When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA. As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area. This study demonstrates that the fabrication of biocompatible C-S MCs is possible, and that the release control of biomolecules is adjustable. Furthermore, MC-mediated GFs remain in an active form and can upregulate the angiogenic activity of ECs. Core-shell microcapsules are fabricated from immiscible, biocompatible poly(L-lactic-co-glycolic acid) (PLGA) and alginate by using an electrodropping system. They hold the angiogenic growth factors (GFs) vascular endothelial GF (VEGF) in the shell alginate and platelet-derived GF (PDGF) in the core PLGA. The release profile of biomolecules is tunable by employing layer-by-layer assembly or by changing the polymer molecular weight.

AB - An optimized electrodropping system produces homogeneous core-shell microcapsules (C-S MCs) by using poly(L-lactic-co-glycolic acid) (PLGA) and alginate. Fluorescence imaging clearly shows the C-S domain in the MC. For release control, the use of high-molecular-weight PLGA (HMW 270 000) restrains the initial burst release of protein compared to that of low-MW PLGA (LMW 40 000). Layer-by-layer (LBL) assembly of chitosan and alginate on MCs is also useful in controlling the release profile of biomolecules. LBL (7-layer) treatment is effective in suppressing the initial burst release of protein compared to no LBL (0-layer). The difference of cumulative albumin release between HMW (7-layer LBL) and LMW (0-layer LBL) PLGA is determined to be more than 40% on day 5. When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA. As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area. This study demonstrates that the fabrication of biocompatible C-S MCs is possible, and that the release control of biomolecules is adjustable. Furthermore, MC-mediated GFs remain in an active form and can upregulate the angiogenic activity of ECs. Core-shell microcapsules are fabricated from immiscible, biocompatible poly(L-lactic-co-glycolic acid) (PLGA) and alginate by using an electrodropping system. They hold the angiogenic growth factors (GFs) vascular endothelial GF (VEGF) in the shell alginate and platelet-derived GF (PDGF) in the core PLGA. The release profile of biomolecules is tunable by employing layer-by-layer assembly or by changing the polymer molecular weight.

KW - angiogenesis

KW - core/shell materials

KW - electrodropping

KW - growth factors

KW - microcapsules

UR - http://www.scopus.com/inward/record.url?scp=84886041487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886041487&partnerID=8YFLogxK

U2 - 10.1002/smll.201300427

DO - 10.1002/smll.201300427

M3 - Article

C2 - 23585380

AN - SCOPUS:84886041487

VL - 9

SP - 3468

EP - 3476

JO - Small

JF - Small

SN - 1613-6810

IS - 20

ER -